Haemonetics (NYSE:HAE) Updates FY25 Earnings Guidance

Haemonetics (NYSE:HAE) updated its FY25 earnings guidance on Thursday. The company provided EPS guidance of $4.45-$4.75 for the period, compared to the consensus EPS estimate of $4.40. The company issued revenue guidance of $1.37-$1.41 billion, compared to the consensus revenue estimate of $1.37 billion. Haemonetics also updated its FY 2025 guidance to 4.450-4.750 EPS.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. TheStreet cut shares of Haemonetics from a b- rating to a c+ rating in a report on Thursday, February 29th. Barrington Research reaffirmed an outperform rating and issued a $105.00 target price on shares of Haemonetics in a research report on Friday, April 12th. Finally, StockNews.com lowered Haemonetics from a buy rating to a hold rating in a research report on Friday, March 22nd.

Haemonetics Trading Down 2.0 %

Shares of HAE stock opened at $93.25 on Thursday. Haemonetics has a fifty-two week low of $70.74 and a fifty-two week high of $97.13. The stock has a market cap of $4.74 billion, a P/E ratio of 37.91, a P/E/G ratio of 2.23 and a beta of 0.34. The business has a fifty day simple moving average of $83.59 and a 200-day simple moving average of $82.81. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. The business had revenue of $336.20 million during the quarter, compared to analysts’ expectations of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter last year, the business posted $0.85 earnings per share. On average, analysts forecast that Haemonetics will post 3.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Haemonetics news, EVP Anila Lingamneni sold 2,305 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the sale, the executive vice president now directly owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.79% of the stock is currently owned by company insiders.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.